<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39172652</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8976</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Viral immunology</Title><ISOAbbreviation>Viral Immunol</ISOAbbreviation></Journal><ArticleTitle>Cytokine Profile in Patients with Postacute Sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>346</StartPage><EndPage>354</EndPage><MedlinePgn>346-354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/vim.2024.0025</ELocationID><Abstract><AbstractText>The enduring impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its disease manifestation, COVID-19, on public health remains significant. Postacute sequelae of SARS-CoV-2 infection (PASC) affect a considerable number of patients, impairing their quality of life. While the role of the cytokine storm in acute COVID-19 is well established, its contribution to the pathophysiology of PASC is not fully understood. This study aimed to analyze the cytokine profile of patients with PASC following <i>in vitro</i> stimulation of Toll-like receptor (TLR) pathways, comparing them with a healthy control group. From October 2020 till March 2021, Brugmann University Hospital's clinical research unit included patients with PASC in the study. Whole blood samples were collected from 50 patients and 25 healthy volunteers. After <i>in vitro</i> stimulation under five different conditions, cytokine levels were measured using a multiplex method. Significantly decreased cytokine levels were observed in patients with PASC compared with healthy volunteers, particularly after TLR4 (interleukin [IL]-1<i>&#x3b1;</i>, IL-1<i>&#x3b2;</i>, IL-2, IL-10, interferon (IFN)<i>&#x3b1;</i>, IFN<i>&#x3b3;</i>, IFN<i>&#x3c9;</i>, and tumor necrosis factor (TNF)<i>&#x3b1;</i>) and TLR7/8 (IL-1<i>&#x3b1;</i>, IL-1<i>&#x3b2;</i>, IFN<i>&#x3b1;</i>, IFN<i>&#x3c9;</i>, IFN<i>&#x3b3;</i>, and TNF<i>&#x3b1;</i>) pathway stimulation. Principal component analysis identified two distinct clusters, suggesting a likely dysregulation of immunity involving TLR4 and TLR7/8 pathways in patients with PASC. Our study suggests that TLR4 and TLR7/8 pathways play a role in the pathophysiology of PASC. Continuous basal activation of immunity could explain the high basal concentrations of cytokines described in these patients and the decreased amplitude of response of these signaling pathways following specific stimulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghorra</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8526-7027</Identifier><AffiliationInfo><Affiliation>Department of Immunology, LHUB-ULB (Laboratoire Hospitalier Universitaire de Bruxelles), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popotas</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Translational Research Unit, H&#xf4;pital Universitaire Des Enfants Reine Fabiola, Bruxelles, Belgique.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research Unit, Universit&#xe9; Libre de Bruxelles, CHU Brugmann, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besse-Hammer</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Research, Brugmann University Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Brugmann University Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogiers</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Research, Brugmann University Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Brugmann University Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corazza</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology, LHUB-ULB (Laboratoire Hospitalier Universitaire de Bruxelles), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research Unit, H&#xf4;pital Universitaire Des Enfants Reine Fabiola, Bruxelles, Belgique.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagant</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, LHUB-ULB (Laboratoire Hospitalier Universitaire de Bruxelles), Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Viral Immunol</MedlineTA><NlmUniqueID>8801552</NlmUniqueID><ISSNLinking>0882-8245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CLIA multiplex</Keyword><Keyword MajorTopicYN="N">TLR pathways</Keyword><Keyword MajorTopicYN="N">cytokine profile</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">postacute sequelae of COVID-19</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39172652</ArticleId><ArticleId IdType="doi">10.1089/vim.2024.0025</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>